Trial Profile
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Temozolomide (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Gastric cancer; Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 08 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 08 Jan 2024 Status changed from discontinued to active, no longer recruiting.
- 07 Jun 2022 Status changed from recruiting to discontinued.